1. "Molecular Imaging and Therapy Service"
  2. "Meeting abstract"
Formats
  1. Meeting Abstract (894)
Groups
  1. Molecular Imaging and Therapy Service (894)
  2. Radiology, Department of (875)
  3. GSK Faculty (461)
  4. Department of Medicine (386)
  5. Sloan Kettering Institute Faculty (376)
  6. Molecular Pharmacology and Chemistry Program Faculty (369)

More Groups

People
  1. Steven Larson (344)
  2. Heiko Schoder (187)
  3. Neeta Pandit-Taskar (145)
  4. John Humm (122)
  5. Ronald Finn (81)
  6. Pat Zanzonico (68)

More People

Years
  1. 2023 (60)
  2. 2022 (34)
  3. 2021 (42)
  4. 2020 (46)
  5. 2019 (78)
  6. 2018 (52)

More Years

Publications
  1. Journal of Nuclear Medicine (227)
  2. Journal of Clinical Oncology (177)
  3. Blood (77)
  4. International Journal of Radiation Oncology, Biology, Physics (46)
  5. Cancer Research (42)
  6. European Journal of Nuclear Medicine and Molecular Imaging (42)

More Publications

Publishers
  1. Society of Nuclear Medicine (227)
  2. American Society of Clinical Oncology (177)
  3. American Society of Hematology (77)
  4. Elsevier Inc. (73)
  5. American Association for Cancer Research (62)
  6. Springer (57)

More Publishers

Results (894)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (CHL)
    Meeting Abstract

    LaCasce, A. S.; Dockter, T.; Ruppert, A.; Kostakoglu, L.; Schöder, H.; Hsi, E. D.; Bogart, J. A.; Cheson, B. D.; Wagner‐Johnston, N. D.; Abramson, J. S.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Optimized pretargeting of [(89)Zr]Zr-DO3A-proteus radiohapten in rodent models of human colorectal cancer
    Meeting Abstract

    Le Roux, A.; Cheal, S.; Veach, D.; Ouerfelli, O.; Yang, G.; Longo, V.; Guo, H. F.; Seo, S.; Burnes Vargas, D.; Xu, H.; more...
    Nuclear Medicine and Biology (2021)

    Fulltext@MSK | Save
  • Pretherapeutic first-in-human targeting trial of anti-hK2 antibody h11B6: A potential molecular vector for alpha-particle radioimmunotherapy
    Meeting Abstract

    Morris, M. J.; O' Donoghue, J. A.; Chetty, D.; Max, S.; Wanik, D.; Russell, M.; Nyima, T.; Avadhani, A. N.; Divgi, C. R.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer
    Meeting Abstract

    Chakraborty, G.; Hirani, R.; Nandakumar, S.; Kalidindi, T. M.; Fidele, D.; Rajanala, S. H.; Mazzu, Y. Z.; Yoshikawa, Y.; Jehane, L. E.; Lee, G. S. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE
    Meeting Abstract

    Coffman, K. L.; Bodei, L.; Le, T.; Choi, Y.; Chou, J. F.; Capanu, M.; Dunphy, M.; Fox, J. J.; Grewal, R. K.; Reddy, R.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1
    Meeting Abstract

    Linden, H. M.; Campone, M.; Bardia, A.; Ulaner, G. A.; Gosselin, A.; Doroumian, S.; Pelekanou, V.; Celanovic, M.; Chandarlapaty, S.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Local review versus (vs) central review of fluorodeoxyglucose positron emission tomography (FDG-PET) in diffuse large B-cell lymphoma (DLBCL): Results from the CALGB 50303 trial [alliance]
    Meeting Abstract

    Ruppert, A. S.; Pederson, L. D.; Knopp, M. V.; Poon, D.; Zhang, J.; Kahl, B. S.; Friedberg, J. W.; Schwartz, L. H.; Wilson, W. H.; Leonard, J. P.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study
    Meeting Abstract

    Epstein-Peterson, Z. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Ho, C.; Jacob, A. P.; more...
    Blood (2020)

    Fulltext@MSK | Save